Drug Approval | April 28, 2026
AbbVie seeks FDA nod for subcutaneous SKYRIZI induction in Crohn’s disease
The submission is backed by positive results from the Phase 3 AFFIRM study
The submission is backed by positive results from the Phase 3 AFFIRM study
The approval was driven by data from the Phase III TULIP-SC trial
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
FTIR and machine learning-based technology enables real-time, cost-effective quantification of food adulterants
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
Extending production capabilities to the Americas helps reduce labor costs and inventory complexity for nutraceuticals and other industries while maintaining superior moisture control
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Minimally invasive laser-based procedure restores blood flow in complex arterial blockage, enables next-day discharge and improved mobility
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
Subscribe To Our Newsletter & Stay Updated
